Tumor immunogenicity dictates reliance on TCF1 in CD8+ T cells for response to immunotherapy.

[1]  J. Wolchok,et al.  Clinical implications of T cell exhaustion for cancer immunotherapy , 2022, Nature Reviews Clinical Oncology.

[2]  V. Buchholz,et al.  MYB orchestrates T cell exhaustion and response to checkpoint inhibition , 2022, Nature.

[3]  Charles H. Yoon,et al.  An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes. , 2022, Cancer cell.

[4]  C. Zang,et al.  Tcf1 preprograms the mobilization of glycolysis in central memory CD8+ T cells during recall responses , 2022, Nature Immunology.

[5]  A. Bhutkar,et al.  Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. , 2021, Immunity.

[6]  C. Yun,et al.  Self-reactivity controls functional diversity of naive CD8+ T cells by co-opting tonic type I interferon , 2021, Nature Communications.

[7]  Nikhil S. Joshi,et al.  A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response , 2021, Science Immunology.

[8]  A. Regev,et al.  Conventional type I dendric cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes. , 2021, Immunity.

[9]  Christopher C. Griffith,et al.  Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer , 2021, Nature.

[10]  D. Irvine,et al.  Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer , 2021, Nature Cancer.

[11]  Santiago J. Carmona,et al.  Interpretation of T cell states from single-cell transcriptomics data using reference atlases , 2021, Nature Communications.

[12]  Timothy J. Peters,et al.  Antigen-driven EGR2 expression is required for exhausted CD8+ T cell stability and maintenance , 2021, Nature Communications.

[13]  C. Jewell,et al.  Altering Antigen Charge to Control Self-Assembly and Processing of Immune Signals During Cancer Vaccination , 2021, Frontiers in Immunology.

[14]  P. Catalano,et al.  Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma , 2020, Clinical Cancer Research.

[15]  A. Anderson,et al.  T cell factor 1: A master regulator of the T cell response in disease , 2020, Science Immunology.

[16]  Raphael Gottardo,et al.  Integrated analysis of multimodal single-cell data , 2020, Cell.

[17]  S. Thomas,et al.  Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy , 2020, Science Translational Medicine.

[18]  L. Boon,et al.  The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. , 2020, Cancer cell.

[19]  D. Ye,et al.  Identification of new susceptibility loci associated with rheumatoid arthritis , 2020, Annals of the Rheumatic Diseases.

[20]  M. Mann,et al.  Dynamics in protein translation sustaining T cell preparedness , 2020, Nature Immunology.

[21]  G. Freeman,et al.  Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection. , 2019, Immunity.

[22]  David M. Schauder,et al.  CD4+ T Cell Help Is Required for the Formation of a Cytolytic CD8+ T Cell Subset that Protects against Chronic Infection and Cancer. , 2019, Immunity.

[23]  Howard Y. Chang,et al.  c-Jun overexpression in CAR T cells induces exhaustion resistance , 2019, Nature.

[24]  S. Berger,et al.  TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision. , 2019, Immunity.

[25]  W. Birchmeier,et al.  SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling , 2019, Front. Immunol..

[26]  Simon C. Potter,et al.  Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility , 2019, Science.

[27]  G. Freeman,et al.  Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. , 2019, Immunity.

[28]  M. Delorenzi,et al.  TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection , 2019, Nature.

[29]  Yong Liu,et al.  TOX is a critical regulator of tumour-specific T cell differentiation , 2019, Nature.

[30]  S. Berger,et al.  TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion , 2019, Nature.

[31]  P. Hogan,et al.  TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion , 2019, Proceedings of the National Academy of Sciences.

[32]  Vinay Prasad,et al.  Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs , 2019, JAMA network open.

[33]  Elisabeth F. Heuston,et al.  Single-Cell RNA-Seq Reveals TOX as a Key Regulator of CD8+ T cell Persistence in Chronic Infection , 2019, Nature Immunology.

[34]  F. Hodi,et al.  Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade , 2019, Nature Immunology.

[35]  I. Amit,et al.  Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma , 2019, Cell.

[36]  Aviv Regev,et al.  Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD‐1−CD8+ Tumor‐Infiltrating T Cells , 2019, Immunity.

[37]  Daniel E. Speiser,et al.  Intratumoral Tcf1+PD‐1+CD8+ T Cells with Stem‐like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy , 2019, Immunity.

[38]  Paul J. Hoover,et al.  Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma , 2019, Cell.

[39]  M. Kneilling,et al.  Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. , 2018, JCI insight.

[40]  Ralph Weissleder,et al.  Successful Anti‐PD‐1 Cancer Immunotherapy Requires T Cell‐Dendritic Cell Crosstalk Involving the Cytokines IFN‐&ggr; and IL‐12 , 2018, Immunity.

[41]  Francesco Ferrari,et al.  High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors , 2018, The Journal of experimental medicine.

[42]  C. Klein,et al.  A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade , 2018, Nature Medicine.

[43]  L. Coussens,et al.  TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. , 2018, Cancer cell.

[44]  J. Aerts,et al.  SCENIC: Single-cell regulatory network inference and clustering , 2017, Nature Methods.

[45]  Sean C. Bendall,et al.  Systemic Immunity Is Required for Effective Cancer Immunotherapy , 2017, Cell.

[46]  Aviv Regev,et al.  A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells , 2016, Cell.

[47]  Avinash Bhandoola,et al.  TCF-1 upregulation identifies early innate lymphoid progenitors in the bone marrow , 2015, Nature Immunology.

[48]  P. Rochaix,et al.  Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma. , 2015, Cancer research.

[49]  H. Koblish,et al.  Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.

[50]  M. Pirinen,et al.  Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis , 2013, Nature Genetics.

[51]  Ludo Waltman,et al.  A smart local moving algorithm for large-scale modularity-based community detection , 2013, The European Physical Journal B.

[52]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[53]  J. Harty,et al.  Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1. , 2010, Immunity.

[54]  Dietmar Zehn,et al.  Complete but curtailed T cell response to very low affinity antigen , 2009, Nature.

[55]  L. Ailles,et al.  Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences , 2000, Nature Genetics.

[56]  K. Losos,et al.  An enhancer that directs lineage-specific expression of CD8 in positively selected thymocytes and mature T cells. , 1997, Immunity.